SuperworthCompass Therapeutics revenue CMPX
Sales by quarter and over the last twelve months, from 2023.
- Last 12 months, to Dec 31, 2025
- n/m
- a quarter missing
- Latest quarter, Q4 FY25
- $0
- Fiscal year 2025
- n/a
Compass Therapeutics' twelve-month revenue can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q4 FY25, it was $0.
Revenue over time
Fiscal year by fiscal year
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2025 | n/a | n/a |
| FY2024 | n/a | n/a |
| FY2023 | n/a | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier |
|---|---|---|---|
| Q4 FY25 | $0 | n/a | |
| Q3 FY25 | $0 | n/a | |
| Q2 FY25 | $0 | −100% | |
| Q4 FY24 | $0 | n/a | |
| Q3 FY24 | $0 | n/a | |
| Q2 FY24 | $850K | n/a | |
| Q4 FY23 | $0 | n/a | |
| Q3 FY23 | $0 | n/a | |
| Q2 FY23 | $0 | n/a |
Against its peers
Companies in Healthcare nearest Compass Therapeutics' size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| CMPXCompass Therapeutics | n/m | |
| KEQUKewaunee Scientific | $277.2M | +5% a year |
| PDEXPro DEX | $77.5M | +16% a year |
| ICCCImmucell | $30.7M | +8% a year |
| PLXProtalix BioTherapeutics | $80.6M | +30% a year |
| NATRNatures Sunshine Products | $492M | +7% a year |
| ELMDElectromed | $73.8M | +15% a year |
| UTMDUtah Medical Products | $36.1M | −7% a year |
| LFVNLifevantage | $182.6M | −20% a year |
| INFUInfuSystem | $143.3M | +2% a year |
| SPROSpero Therapeutics | $47M | −3% a year |
| Peer median | $79.1M |
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on Compass Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.